uracil has been researched along with Chronic Kidney Failure in 13 studies
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder
| Excerpt | Relevance | Reference |
|---|---|---|
| "5%) patients (calcium channel blockers, ACE inhibitors, statins, diuretics, tacrolimus); four patients required further adjustment of antihypertensive drugs or tacrolimus dosage on-treatment." | 5.48 | Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir Regimen in the Treatment of Genotype 1 Chronic Hepatitis C Infection in Patients with Severe Renal Impairment and End-Stage Renal Disease: a Real-Life Cohort. ( Chmelova, K; Frankova, S; Kreidlova, M; Merta, D; Senkerikova, R; Sperl, J, 2018) |
| " In the double-blind phase, the incidence of treatment-emergent adverse events (TEAEs) was 72." | 2.94 | Efficacy and safety of trelagliptin in Japanese patients with type 2 diabetes with severe renal impairment or end-stage renal disease: Results from a randomized, phase 3 study. ( Achira, M; Ishida, K; Kaku, K; Shimizu, K; Umeda, Y, 2020) |
| "However, the best strategy to identify DPD deficiency in End Stage Renal Disease (ESRD) patients is unknown." | 1.62 | Pretherapeutic screening for Dihydropyrimidine deshydrogenase deficiency in measuring uracilemia in dialysis patients leads to a high rate of falsely positive results. ( Gaible, C; Loriot, MA; Narjoz, C; Pallet, N; Roueff, S, 2021) |
| "5%) patients (calcium channel blockers, ACE inhibitors, statins, diuretics, tacrolimus); four patients required further adjustment of antihypertensive drugs or tacrolimus dosage on-treatment." | 1.48 | Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir Regimen in the Treatment of Genotype 1 Chronic Hepatitis C Infection in Patients with Severe Renal Impairment and End-Stage Renal Disease: a Real-Life Cohort. ( Chmelova, K; Frankova, S; Kreidlova, M; Merta, D; Senkerikova, R; Sperl, J, 2018) |
| "New highly effective treatments for chronic hepatitis C virus (HCV) infection are now available, but safety and efficacy data on the use of anti-HCV therapies in patients with renal failure, particularly those requiring PD, remain limited." | 1.46 | Successful treatment of chronic hepatitis C virus infection in a patient receiving daily peritoneal dialysis. ( Cole, J; Stark, JE, 2017) |
| "A 61-year-old man on hemodialysis due to chronic renal failure caused by diabetes mellitus was diagnosed as having ascending colon cancer with multiple liver metastases." | 1.38 | [A case of stage IV colon cancer effectively treated with tegafur uracil/calcium folinate in a patient on hemodialysis]. ( Kobayashi, M; Maeda, H; Okamoto, K; Takeshita, A, 2012) |
| "In a rat model of chronic renal failure, 5/6-nephrectomized [5/6N] rats were treated orally with DPP-4 inhibitors (linagliptin, sitagliptin, alogliptin) or placebo once daily for 4 days from 8 weeks after surgery, to identify the most appropriate treatment for cardiac dysfunction associated with CKD." | 1.37 | Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy. ( Alter, M; Chaykovska, L; Fuchs, H; Heiden, S; Hocher, B; Klein, T; Rahnenführer, J; Runge, F; von Websky, K, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (69.23) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Gaible, C | 1 |
| Narjoz, C | 1 |
| Loriot, MA | 1 |
| Roueff, S | 1 |
| Pallet, N | 1 |
| Tatar, B | 1 |
| Köse, Ş | 1 |
| Ergun, NC | 1 |
| Turken, M | 1 |
| Onlen, Y | 1 |
| Yılmaz, Y | 1 |
| Akhan, S | 1 |
| Stark, JE | 1 |
| Cole, J | 1 |
| Sperl, J | 1 |
| Kreidlova, M | 1 |
| Merta, D | 1 |
| Chmelova, K | 1 |
| Senkerikova, R | 1 |
| Frankova, S | 1 |
| Yaraş, S | 1 |
| Üçbilek, E | 1 |
| Özdoğan, O | 1 |
| Ateş, F | 1 |
| Altıntaş, E | 1 |
| Sezgin, O | 1 |
| Özer Etik, D | 1 |
| Suna, N | 1 |
| Öcal, S | 1 |
| Selçuk, H | 1 |
| Dağlı, Ü | 1 |
| Çolak, T | 1 |
| Hilmioğlu, F | 1 |
| Boyacıoğlu, AS | 1 |
| Haberal, M | 1 |
| Kaku, K | 1 |
| Ishida, K | 1 |
| Shimizu, K | 1 |
| Achira, M | 1 |
| Umeda, Y | 1 |
| Pockros, PJ | 1 |
| Reddy, KR | 1 |
| Mantry, PS | 1 |
| Cohen, E | 1 |
| Bennett, M | 1 |
| Sulkowski, MS | 1 |
| Bernstein, DE | 1 |
| Cohen, DE | 1 |
| Shulman, NS | 1 |
| Wang, D | 1 |
| Khatri, A | 1 |
| Abunimeh, M | 1 |
| Podsadecki, T | 1 |
| Lawitz, E | 1 |
| Ponziani, FR | 1 |
| Siciliano, M | 1 |
| Lionetti, R | 1 |
| Pasquazzi, C | 1 |
| Gianserra, L | 1 |
| D'Offizi, G | 1 |
| Gasbarrini, A | 1 |
| Pompili, M | 1 |
| Chaykovska, L | 1 |
| von Websky, K | 1 |
| Rahnenführer, J | 1 |
| Alter, M | 1 |
| Heiden, S | 1 |
| Fuchs, H | 1 |
| Runge, F | 1 |
| Klein, T | 1 |
| Hocher, B | 1 |
| Okamoto, K | 1 |
| Kobayashi, M | 1 |
| Maeda, H | 1 |
| Takeshita, A | 1 |
| Sakamoto, K | 1 |
| Arita, S | 1 |
| Hisikawa, E | 1 |
| Yaguchi, H | 1 |
| Arima, H | 1 |
| Matsumoto, M | 1 |
| Hachisu, T | 1 |
| Kashiwabara, H | 1 |
| Yokoyama, T | 1 |
| Yanagisawa, T | 1 |
| Arimoto, T | 1 |
| Kishimoto, H | 1 |
| Takahashi, Y | 1 |
| Urade, M | 1 |
| Yoshioka, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection, With Severe Renal Impairment or End-Stage Renal[NCT02207088] | Phase 3 | 68 participants (Actual) | Interventional | 2014-09-23 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
On-treatment virologic failure was defined as confirmed HCV RNA ≥ LLOQ after < LLOQ during treatment, confirmed increase of > 1 log (subscript)10(subscript) IU/mL above the lowest value post-baseline HCV RNA during treatment, or HCV RNA ≥ LLOQ persistently during treatment with at least 6 weeks of treatment. (NCT02207088)
Timeframe: Up to 24 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| 3-DAA ± RBV | 0 |
Post-treatment relapse was defined as confirmed HCV RNA ≥ LLOQ between end of treatment and 12 weeks after the last dose of study drug among participants completing treatment and with HCV RNA < LLOQ at the end of treatment. (NCT02207088)
Timeframe: Within 12 weeks after the last dose of study drug
| Intervention | percentage of participants (Number) |
|---|---|
| 3-DAA ± RBV | 1.5 |
SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification (
Timeframe: 12 weeks after the last actual dose of study drug
| Intervention | percentage of participants (Number) |
|---|---|
| 3-DAA ± RBV | 94.1 |
3 trials available for uracil and Chronic Kidney Failure
| Article | Year |
|---|---|
Efficacy and safety of trelagliptin in Japanese patients with type 2 diabetes with severe renal impairment or end-stage renal disease: Results from a randomized, phase 3 study.
Topics: Aged; Asian People; Diabetes Mellitus, Type 2; Diet Therapy; Dipeptidyl-Peptidase IV Inhibitors; Dou | 2020 |
Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Dose-Response Relation | 2016 |
[Pharmacokinetic study of UFT in cancer patients receiving maintenance dialysis].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 1995 |
10 other studies available for uracil and Chronic Kidney Failure
| Article | Year |
|---|---|
Pretherapeutic screening for Dihydropyrimidine deshydrogenase deficiency in measuring uracilemia in dialysis patients leads to a high rate of falsely positive results.
Topics: Case-Control Studies; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP) | 2021 |
Response to direct-acting antiviral agents in chronic hepatitis C patients with end-stage renal disease: a clinical experience.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, C | 2019 |
Successful treatment of chronic hepatitis C virus infection in a patient receiving daily peritoneal dialysis.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Sc | 2017 |
Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir Regimen in the Treatment of Genotype 1 Chronic Hepatitis C Infection in Patients with Severe Renal Impairment and End-Stage Renal Disease: a Real-Life Cohort.
Topics: 2-Naphthylamine; Anilides; Antihypertensive Agents; Antiviral Agents; Carbamates; Cyclopropanes; Dru | 2018 |
Real-life results of treatment with ombitasvir, paritaprevir, dasabuvir, and ritonavir combination in patients with chronic renal failure infected with HCV in Turkey.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, C | 2019 |
Successful Treatment With Direct-Acting Antiviral Agents of Hepatitis C in Patients With End-Stage Renal Disease and Kidney Transplant Recipients.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Interactio | 2019 |
Effectiveness of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir in Hemodialysis Patients With Hepatitis C Virus Infection and Advanced Liver Fibrosis: Case Reports.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; H | 2017 |
Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy.
Topics: Animals; Area Under Curve; Cardiomyopathies; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibit | 2011 |
[A case of stage IV colon cancer effectively treated with tegafur uracil/calcium folinate in a patient on hemodialysis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colectomy; Colonic Neoplasms; Combined Modality Ther | 2012 |
[Dynamic change of serum UFT concentration in a patient with tongue cancer complicating chronic renal failure].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell | 1995 |